Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon therapy for chronic hepatitis C

G L Davis1

  • 1Section of Hepatobiliary Disease, University of Florida, Gainesville 32610, USA.

Bailliere'S Clinical Gastroenterology
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018-2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).

The Journal of hospital infection·2022
Same author

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

Journal of viral hepatitis·2014
Same author

Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Radium content of ultramafic igneous rocks; laboratory investigation.

American journal of science·2010
Same author

Planning the hospital for community service.

Minnesota medicine·2010
Same journal

Index.

Bailliere's clinical gastroenterology·2020
Same journal

Home enteral and parenteral nutrition in children.

Bailliere's clinical gastroenterology·1999
Same journal

Nutritional support in malnourished paediatric patients.

Bailliere's clinical gastroenterology·1999
Same journal

Cholestasis and end-stage liver disease.

Bailliere's clinical gastroenterology·1999
Same journal

Cystic fibrosis: nutritional consequences and management.

Bailliere's clinical gastroenterology·1999
Same journal

Pancreatic diseases (excluding cystic fibrosis).

Bailliere's clinical gastroenterology·1999
See all related articles

Interferon is the primary treatment for chronic hepatitis C, but patient response varies. Future treatments will likely be personalized based on individual factors and advanced viral level monitoring.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis C is primarily treated with interferon.
  • Treatment effectiveness varies significantly among patients.
  • Factors influencing response include liver histology, viral genotype, and viral load.

Purpose of the Study:

  • To explore the factors influencing interferon treatment response in chronic hepatitis C.
  • To discuss the future of personalized treatment regimens for hepatitis C.
  • To highlight the evolving role of quantitative viral assays in patient management.

Main Methods:

  • Review of current clinical studies on interferon therapy for chronic hepatitis C.
  • Analysis of factors affecting patient response to interferon.

Related Experiment Videos

  • Discussion of emerging diagnostic technologies for hepatitis C viral levels.

    • Main Results:

    • Interferon response is influenced by multiple patient-specific factors.
    • Current treatment regimens are being refined through ongoing clinical research.
    • Advanced assays will enable more precise monitoring of treatment efficacy.

    Conclusions:

    • Future chronic hepatitis C treatment will likely involve personalized regimens.
    • Quantitative viral load monitoring will transform treatment strategies.
    • Chronic hepatitis C may be increasingly viewed as a curable infection rather than a chronic liver disease.